News

Florin Despa says that a major scientific goal is to understand whether the same factors that are involved in age-related metabolic disorders such as type-2 diabetes may also play a role in the development and progression of cognitive decline and dementia.

Dr. Peter Nelson, of the University of Kentucky’s Sanders-Brown Center on Aging, has spent the last 15 years in the Commonwealth helping to lead the fight against Alzheimer’s and dementia inducing brain disease.

In the sessions for both the scientific and community audience, attendees will have the opportunity to hear clinicians and researchers from UK and other institutions share current findings, trends, and latest updates on dementia and aging disorders.

Selenica says their study is the first to provide a novel pathway and identify potential therapeutic targets for TDP-43 proteinopathies – especially in Alzheimer’s disease and the newly characterized form of dementia known as LATE.

Through the group's work, they found that the therapeutic targeting of TREM2 using a TREM2-activating antibody leads to the activation of microglia, recruitment of microglia to amyloid plaques, reduced amyloid deposition, and ultimately improved cognition.

“We used to think that aging-related memory and thinking decline meant one thing: a disease called Alzheimer’s disease. Now we know that the disease we were calling Alzheimer’s disease is actually many different conditions, often in combination."

Researchers will be looking at a medication that recently received experimental approval from the USDA and its impact on the newly characterized form of dementia known as LATE. LATE is a disease with symptoms similar to Alzheimer’s disease.

The long-running study on aging and brain health at UK’s Sanders-Brown Center on Aging (SBCoA) Alzheimer’s Disease Center has once again resulted in important new findings – highlighting a complex and under-recognized form of dementia.

An international group of experts led by Dr. Peter Nelson, a neuropathologist at the UK Sanders-Brown Center on Aging, is being recognized as one of the top science stories of 2019 by Discover Magazine.

Researchers at UK's College of Medicine have found that a class of antibiotics could be promising treatment for a form of dementia. Results of their proof of concept study were recently published in the journal Human Molecular Genetics.